Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.93), $0.16 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $9.33 million versus the consensus estimate of $5.19 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.